Precision BioSciences
NASDAQ: DTILDurham, US · Delaware corporation · 11 known investors
Find your way into Precision BioSciences
497 people in our graph share verified history with the Precision BioSciences team — schools, employers, funds. One of them is your warm intro.
Michel Abadiunlockedknows TODD MELBY · together at Northwestern University - Kellogg School of Management (overlapped)
×3knows the team · via Duke University
×2knows the team · via Northwestern University - Kellogg School of Management
×2knows the team · via The Johns Hopkins University School of Medicine
×2knows the team · via Rose-Hulman Institute of Technology
×2knows the team · via Rider University
Precision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).
Founders & leadership
DJ
DEREK JANTZinCo-founder · Chief Science AdvisorDerek Jantz is a biotech entrepreneur with experience developing gene and cell therapies from early stages through clinical proof-of-concept, having led research teams of over 150 scientists in both startup and public company settings. As a co-founder of Precision BioSciences, he contributed to the company's gene-editing platform and has overseen the development of multiple therapeutic programs, including five that have advanced to clinical trials.
MK
MATTHEW KANECo-founder
JS
Jeff SmithinCo-founderJeff Smith is a molecular biologist with approximately three decades of experience in protein engineering, including directed evolution and computational methods. He has held leadership roles managing scientific teams and holds multiple patents in the field.
DJ
Derek JantzinCo-founderDerek Jantz is a co-founder of Precision BioSciences who has led research teams in biotech environments and contributed to early development of gene editing technology as an academic scientist. He has overseen development of multiple gene-edited therapeutic programs, several of which have advanced to clinical trials.
TM
TODD MELBYinChief Operating Officer2015–2018Todd Melby served as President of Leadership Edge, a leadership development organization, and has held senior operational leadership roles scaling companies across agriculture, gene therapy, and immuno-oncology sectors.
MA
Michael AmorosoinPresident & CEOAmoroso previously served as chief executive officer and board chairman at Abeona Therapeutics, which he joined as chief commercial and operating officer in 2020. Earlier in his career he was senior vice president and chief commercial officer at Kite Pharma, led the Americas oncology commercial business at Eisai US, and held global marketing and CAR T commercial roles at Celgene.
Board
RA
ROBERT ADELMANBoard directorCo-founder and Emeritus Managing Partner at venBio Partners
BA
BEN AUSPITZBoard director
Investors · 11
age1San Francisco · $500K – $4M
Agent CapitalWaltham
Aliment CapitalLos Angeles · $3M – $5M
Brace PharmaAtlanta
F-Prime CapitalCambridge · $3M – $10M
OCV PartnersLos Angeles
OUP (Osage University Partners)Bala Cynwyd · $1M – $20M
Pontifax AgTechSanta Monica
RA CapitalBoston
venBio PartnersSan Franciscovia Robert Adelman · board
Vivo CapitalPalo Alto · $10M – $50M
Reported raises · per SEC filings
Form D private placements$153.3M disclosed across 3 of 5 rounds · 2015–2026
▶$39.5MraisedMar 2019 · 23 investors · BiotechnologyRule 506(b)
▶$39.5MraisedMar 2019 · 23 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Derek JantzExecutive Officer, Director
- Matthew KaneExecutive Officer, Director
- Robert AdelmanDirector
- Shalini SharpDirector
- Jeff SmithExecutive Officer
- Abid AnsariExecutive Officer
- Tony YaoDirector
- Offering amount
- $70M
- Amount sold
- $39.5M
- First sale
- Mar 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$88.1MraisedJun 2018 · 40 investors · BiotechnologyRule 506(b)
▶$88.1MraisedJun 2018 · 40 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Derek JantzExecutive Officer, Director
- Tony YaoDirector
- Matthew KaneExecutive Officer, Director
- Abid AnsariExecutive Officer
- Jeff SmithExecutive Officer
- Robert AdelmanDirector
- Offering amount
- $110M
- Amount sold
- $88.1M
- First sale
- May 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$25.6MraisedMay 2015 · 11 investors · BiotechnologyRule 506(b)
▶$25.6MraisedMay 2015 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- JEFF SMITHExecutive Officer
- ROBERT ADELMANDirector
- DEREK JANTZExecutive Officer, Director
- MATTHEW KANEExecutive Officer, Director
- TODD MELBYExecutive Officer
- BEN AUSPITZDirector
- Offering amount
- $25.6M
- Amount sold
- $25.6M
- First sale
- Apr 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$784.5Mvaluation at IPOMar 2019 · $16.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Founder mafia
2 people who came through Precision BioSciences went on to found or lead other companies.
Competitors · 2
by search overlapLife Biosciences78 shared keywordsLongevity company with diversified therapies to extend healthy human lifespan
IQVIA76 shared keywordsIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Companies competing with Precision BioSciences for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Precision BioSciences Q2 2026 results: Warrant revaluation widens the net losstradingkey.com · Aug 2026
Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update - BioSpacebiospace.com · Aug 2026Frequently asked questions
- What does Precision BioSciences do?
- Precision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).
- Who founded Precision BioSciences?
- Precision BioSciences was founded by DEREK JANTZ, MATTHEW KANE, Jeff Smith, Derek Jantz.
- Who are Precision BioSciences's investors?
- Precision BioSciences's investors include age1, Agent Capital, Aliment Capital, Brace Pharma, F-Prime Capital, OCV Partners, OUP (Osage University Partners), Pontifax AgTech and 3 more.
- How much funding has Precision BioSciences raised?
- Precision BioSciences has disclosed $153.3M raised across 3 of its 5 known rounds.
- Where is Precision BioSciences headquartered?
- Precision BioSciences is headquartered in Durham, US.